The new packaging system will increase Ritedose's annual processing range by between 160 and 170 million vials.

When pressed for 2025 expectations, Verona believed $254 million in revenues was a fair estimate. Critically, Verona expects ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

If you need financial support to pay for Ohtuvayre, or if you need help understanding your insurance coverage, help is available. For example: A program called Verona Pathway Plus is available for ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

Verona Pharma (VRNA ... Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and ...

Verona Pharma is a biopharmaceutical company ... of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre TM (ensifentrine) is the Company’s first commercial product ...